MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY

Trial Profile

MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Dolutegravir (Primary) ; HIV protease inhibitors
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms OSTEODOLU
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 27 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top